A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 12 Jul 2019 Planned initiation date changed from 1 May 2019 to 1 Aug 2019.
- 20 Mar 2019 Planned initiation date changed from 1 Oct 2018 to 1 May 2019.
- 21 Aug 2018 New trial record